Brainclinics Foundation’s Post

Neuroinflammation in Psychiatry 🚨 - CFS / ME / Long Covid / POTS ... It's become more important than ever for psychiatrists to learn about neuroinflammation and understand its implications with the increase in presentations of Long Covid, CFS, POTS, etc. Neuroinflammation is a key player behind the scenes in treatment resistance within psychiatry, entangling with mitochondrial functions, neurotransmitter systems, the immune-endocrine systems, the endothelium and more... In this short snippet from our 10-hour accredited course, I touch on the ME/ CFS and Long Covid Overlap. So please Grab a cup of☕️, and let's go back in time. (15 min video - time limit) "In history, a great volume is unrolled for our instruction, drawing the materials of future wisdom from the past errors and infirmities of mankind". (Burke) So, In this video, I take you back to 2020, then a decade ago to 2013, and then from there, you will go back to 1975. From there, you will come to the present and realise why the overlaps between CFS / ME and Long Covid are unsurprising. Research is split between Dysautonomia, MCA, EDS, #CFS, and #LongCovid when, really, the multiple specialities should be coming together! Patient consent was obtained for images (some modified)—big thanks to Prof Graham Hughes. Our 10-hour accredited course journeys into CFS, Long COVID, Fibromyalgia, MCA (Mast Cell Activation Syndrome), EDS (Ehlers-Danlos Syndromes), and POTS equips clinicians with a comprehensive guide to navigate these complex conditions. We link pharmacological (and non-pharmacological) treatments to underlying pathophysiologies, illustrated through case studies, enabling a more nuanced understanding and management of these conditions. You can learn lots more (10 hrs) in the Neuropsychiatry of #CFS / LC and #Fibromyalgia course. (Academy membership) 👉https://lnkd.in/gTY-iVn3 Individual purchase 👉https://lnkd.in/gEKicSRu #CFS #ME #longcovid #POTS

Some excellent Tuesday reading here on #neuroplasticity as the emerging framework for depression biology. As the psychiatry field rapidly evolves, it can be challenging to overcome old perceptions among the general public and clinicians. This is particularly true for depression therapies, where terms like 'chemical imbalance' are still widely used. Here, Page et al. highlight how "the serotonin deficit hypothesis of major depressive disorder (MDD) has continued to persist despite insufficient supporting evidence" Page also emphasizes communicating how "effective treatments for MDD enhance neuroplasticity mechanisms to restore synaptic, network, and behavioral function to facilitate cognitive and emotional processing" Gate Neuro is committed to advancing next-generation treatments for depression, and other CNS diseases, that target core neuroplasticity biology for better patient outcomes #neuroplasticity #synapticplasticity #drugdevelopment #biotech

An analysis of 15,000 de-identified Tempus nP PGx patient records, recently published in Molecular Psychiatry, revealed that 65% of patients had CYP2D6 and CYP2C19 phenotypes actionable for medication prescribing. More than half of the top 25 most frequently prescribed medications in psychiatry are metabolized by CYP2D6 and CYP2C19, emphasizing the importance of these findings. Access the full manuscript here: https://tempus.co/3VMYjZW

𝗔𝗿𝘁𝗶𝗰𝗹𝗲 𝗧𝗶𝗽💡AI breakthrough: faster match between patient and antidepressant A new AI-driven method developed by Dutch researchers can now predict whether the antidepressant sertraline has an effect using brain scans and questionnaires. The technique has already made correct predictions in two-thirds of cases. This could shorten the treatment time to assess a drug’s effectiveness from months to just one week. Scientists from Amsterdam UMC and Radboudumc have developed a predictive model that can predict the effectiveness of sertraline by analyzing brain scans and questionnaires. The study, published in the American Journal of Psychiatry, highlights the role of brain perfusion as an indicator and has the potential to improve treatment protocols for depression dramatically. Read the full article here👇 https://lnkd.in/eqT2_mHw #artificialintelligence #antidepressant

One size does not fit all. Glad to have co-authored this invited article with Stögmann Elisabeth for Jatros Neurology and Psychiatry. We provide a short update on sex differences in #Alzheimer and why they are going to be relevant in clinical practice and trials. We argue that, as new drugs are appearing for the treatment of Alzheimer, we will need a personalized approach to select patients who are more likely to respond (with low side effects) and adjust regimens. Biological sex will be one of the variables to consider; one-size-fits-all will not work, in my opinion. Link in comments (article in German). #gendermedicine #precisionmedicine #sexdifferences

Congratulations to Elsevier Senior Acquisitions Editor Joslyn Chaiprasert-Paguio and book editors JOÃO LUCIANO DE QUEVEDO (McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston), André R. Brunoni (USP - Universidade de São Paulo), and Clement Hamani (Sunnybrook Research Institute) for the publication of "Interventional Psychiatry: Road to Novel Therapeutics". Authored by leading experts and internationally contributed, this comprehensive guide explores the full spectrum of specialized interventions, from established methods like electroconvulsive therapy (ECT) to cutting-edge approaches such as ketamine infusion therapy and psychedelic therapies. Here's what makes this book a must-read: 🔍 Seamlessly blends established and emerging methodologies, offering a fresh perspective on psychiatric intervention. 🔍 Dives deep into the mechanisms behind interventions, providing invaluable insights into their efficacy. 🔍 With clear indications, contraindications, and techniques, this resource is designed to be practical and accessible. 🔍 For those looking to specialize, the book outlines guidelines for fostering fellowships in Interventional Psychiatry, shaping the future of the field. Perfect for Psychiatrists, Psychologists, Neurologists, and Neurosurgeons—whether in academic or private practice settings. #InterventionalPsychiatry #MentalHealth #Innovation #PsychiatricTreatment

My latest with Helen Lavretsky in Translational Psychiatry! Randomized, controlled trial to assess the efficacy of Kundalini yoga training (KY) compared to memory enhancement training (MET) on mood and cognitive functioning in a group of older women with cerebrovascular risk factors and subjective cognitive decline (NCT03503669). At 24-weeks follow-up, KY yielded a significant, large effect size improvement in subjective cognitive impairment measures compared to MET. On a transcriptional level, at 12- and 24-week follow-up, KY uniquely altered aging-associated signatures, including interferon gamma and other psycho-neuro-immune pathways. Levels of chemokine eotaxin-1, an aging marker, increased over time in MET but not KY participants. https://lnkd.in/gH5H4w-i

I am excited to share this new study from Translational Psychiatry that shows the potential of a novel brain stimulation technique called Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) in reducing suicidal ideation in patients with major depressive disorder (MDD). This is a groundbreaking discovery that could pave the way for more effective and rapid interventions for patients with MDD who are at high risk of suicide. I encourage you to read the full article here and learn more about this innovative and promising therapy.

New research from King's College London reveals a significant association between reduced grey matter in the brain and Early Onset Psychosis (EOP), with the largest-ever brain imaging study in EOP showing decreased grey matter across nearly all brain regions. The study involved 482 individuals with EOP compared to 469 healthy controls from international sites, providing unprecedented detail about the illness. Researchers hope the detailed brain mapping will aid future diagnosis and treatment tracking for EOP, which manifests before age 18 and presents challenges in understanding due to limited research. #BrainResearch #PsychiatryInsights #EarlyOnsetPsychosis